IDEXX Laboratories, Inc. $IDXX Holdings Decreased by Quantum Capital Management LLC NJ

Quantum Capital Management LLC NJ trimmed its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 76,446 shares of the company’s stock after selling 1,379 shares during the quarter. IDEXX Laboratories accounts for about 6.0% of Quantum Capital Management LLC NJ’s holdings, making the stock its 8th biggest holding. Quantum Capital Management LLC NJ owned approximately 0.10% of IDEXX Laboratories worth $51,718,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Virtus Advisers LLC purchased a new position in IDEXX Laboratories in the 3rd quarter worth $26,000. Park Place Capital Corp bought a new stake in IDEXX Laboratories in the fourth quarter worth $29,000. Mowery & Schoenfeld Wealth Management LLC lifted its stake in IDEXX Laboratories by 58.8% in the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock worth $37,000 after purchasing an additional 20 shares during the last quarter. Wormser Freres Gestion lifted its stake in IDEXX Laboratories by 671.4% in the fourth quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock worth $37,000 after purchasing an additional 47 shares during the last quarter. Finally, WealthCollab LLC bought a new stake in IDEXX Laboratories in the second quarter worth $30,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on IDXX shares. Citigroup started coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target for the company. UBS Group lowered their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Wall Street Zen raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Stifel Nicolaus lowered their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Seven investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock opened at $560.88 on Friday. The firm has a market cap of $44.24 billion, a PE ratio of 41.30, a price-to-earnings-growth ratio of 3.05 and a beta of 1.55. IDEXX Laboratories, Inc. has a 12-month low of $506.91 and a 12-month high of $769.98. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The company’s fifty day simple moving average is $563.06 and its two-hundred day simple moving average is $627.69.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The company’s revenue was up 14.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, equities analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.